<DOC>
	<DOCNO>NCT00631449</DOCNO>
	<brief_summary>The purpose study determine whether treatment Raltegravir decrease HIV viral replication HAART-suppressed , HIV-infected patient , potentially improve immune response antiretroviral therapy .</brief_summary>
	<brief_title>Raltegravir Intensification HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Stable antiretroviral therapy least 12 month Screening CD4+ T cell count &lt; 350 cells/mm3 All available CD4+ T cell count last year screen &lt; 350 cells/mm3 Screening plasma HIV RNA level level detection ( &lt; 50 copy RNA/mL use Roche Amplicor &lt; 75 copies/mL use Bayer bDNA &lt; 40 copies/mL use Abbott RTPCR ) , available determination past 12 month also level detection ( isolated single value &gt; 75 &lt; 1000 copies/mL allow precede followed undetectable viral load determination ) . &gt; 90 % adherence therapy within precede 30 day , determine selfreport Both male female adult ( least 18 year old ) subject eligible . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . Patients intend modify antiretroviral therapy next 24 week reason Serious illness require hospitalization parental antibiotic within precede 3 month **Any vaccination 2 week prior baseline ( day 0 ) visit throughout study period Concurrent treatment immunomodulatory drug , exposure immunomodulatory drug past 16 week Concurrent treatment phenobarbital , phenytoin , rifampin . Screening absolute neutrophil count &lt; 1,000 cells/mm3 , platelet count &lt; 70,000 cells/mm3 , hemoglobin &lt; 8 mg/dL , estimate creatinine clearance &lt; 40 mL/minute Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment intensification</keyword>
	<keyword>Low level viremia</keyword>
	<keyword>Suboptimal CD4+ T cell response</keyword>
	<keyword>treatment experience</keyword>
</DOC>